These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27880982)

  • 1. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
    Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM
    Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
    Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
    Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
    J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 6. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
    Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
    Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splanchnic vein thrombosis in myeloproliferative neoplasms.
    Sekhar M; McVinnie K; Burroughs AK
    Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
    De Stefano V; Qi X; Betti S; Rossi E
    Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splanchnic vein thrombosis associated with myeloproliferative neoplasms.
    Tremblay D; Winters A; Beckman JD; Naymagon L; Patel R; Mascarenhas J; Schiano TD
    Thromb Res; 2022 Oct; 218():8-16. PubMed ID: 35963121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
    Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
    Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
    Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
    Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
    Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
    Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 15. γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.
    Görtzen J; Hunka LM; Vonnahme M; Praktiknjo M; Kaifie A; Fimmers R; Jansen C; Heine A; Lehmann J; Goethert JR; Gattermann N; Goekkurt E; Platzbecker U; Brossart P; Strassburg CP; Brummendorf TH; Koschmieder S; Wolf D; Trebicka J
    Medicine (Baltimore); 2016 May; 95(20):e3355. PubMed ID: 27196445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis.
    Ümit EG; Baysal M; Kırkızlar HO; Demir AM
    Turk J Haematol; 2024 Aug; 41(3):175-181. PubMed ID: 38801033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
    Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
    Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
    Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
    Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
    How J; Zhou A; Oh ST
    Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.